Synaptogenix Inc (SNPX)

[Cyosol]

Now that I think about it, didn't they already check patients on Aricept after the #202 trial and decide to keep them in because there was no significant difference between them and previously drug-free patients? I don't remember what the reason was.

In that case a lower score than Aricept might still mean patients can get additional benefits from taking both of them at the same time, since patients on Aricept will presumably already be on the decline before using Bryo.

It also depends on if the curve flattens or declines after 15 weeks for bryo patients I think. If the 13 week slope for combined bryo data stays the same (about +0.3/week) then that would imply an improvement of about 8.4 after 28 weeks, but that's a big if.